Novel sandwich immunoassays for the measurement of total and active FGF21

Bioanalysis

Volumn 6, Issue 24, 2014, Pages 3283-3293

  Umberger, Tara S ^a   Sloan, John H ^a   Chen, Jinbiao ^a   Cheng, Christine ^a   Siegel, Robert W ^a   Qian, Yuewei ^a   Troutt, Jason S ^a   Konrad, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOASSAY; LIMIT OF QUANTITATION; MALE; MEASUREMENT ACCURACY; NORMAL HUMAN; POSTPRANDIAL STATE; PROTEIN BINDING; PROTEIN DOMAIN; QUALITY CONTROL; SANDWICH IMMUNOASSAY; SENSITIVITY ANALYSIS; VOLUNTEER; ADOLESCENT; BLOOD; CALIBRATION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CALIBRATION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84919794261     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.241     Document Type: Article

References (25)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492(1), 203-206 (2000
2. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. (Oxf) 71, 369-375 (2009
3. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett. 582(27), 3805-3810 (2008
4. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115(6), 9 (2005
5. Kharitonenkov A, Dunbar JD, Bina H, et al. FGF-21/FGF-21 receptor interaction and activation is determined by bKlotho. J. Cell. Physiol. 215(1), 1-7 (2007
6. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol Chem. 282(37), 26687-26695 (2007
7. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 22(1), 37-44 (2008
8. Ogawa Y, Kurosu H, Yamamoto H, et al. BKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl Acad. Sci. USA 104(18), 7432-7437 (2007
9. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22(4), 1006-1014 (2008
10. Adams AC, Yang C, Coskun T, et al. The breadth of FGF21' metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2(1), 31-37 (2012
11. Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 7(3), e33870 (2012
12. Yie J, Wang W, Deng L, et al. Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: Structural requirements and implications in FGF21 signaling. Chem. Biol. Drug Des. 79(4), 398-410 (2012
13. Adams AC, Coskun T, Rovira AR, et al. Fundamentals of FGF19 and FGF21 action in vitro and in vivo. PLoS ONE 7(5), e38438 (2012
14. Micanovic R, Raches DW, Dunbar JD, et al. Different roles of N- And C- Termini in the functional activity of FGF21. J. Cell. Physiol. 219(2), 227-234 (2009
15. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. FGF21 requires betaklotho to act in vivo. PLoS ONE 7(11), e49977 (2012
16. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5(6), 426-437 (2007
17. Lefebvre P, Chinetti G, Fruchart J, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J. Clin. Invest. 116(3), 571-580 (2006
18. Lundasen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 360(2), 437-440 (2007
19. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-Activated receptor gamma and altered metabolic states. Mol. Pharmacol. 74(2), 403-412 (2008
20. Moyers JS, Shiyanova TL, Mehrbod F, et al. Molecular determinants of FGF-21 activity-synergy and cross-Talk with PPARgamma signaling. J. Cell Physiol. 210(1), 1-6 (2007
21. Qiang L, Accili D. FGF21 and the second coming of PPARgamma. Cell 148(3), 397-398 (2012
22. Inagaki T, Dutchak P, Zhao G, et al Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5(6), 415-425 (2007
23. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8(2), 169-174 (2008
24. Andersen B, Beck-Nielsen H, Hojlund K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin. Endocrinol. (Oxf) 75(4), 514-519 (2011
25. Yie J, Hecht R, Patel J, et al. FGF21 N- And C-Termini play different roles in receptor interaction and activation. FEBS Lett. 583(1), 19-24 (2009